{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:05:10Z","timestamp":1772028310314,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81920108004"],"award-info":[{"award-number":["81920108004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04513-3","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T13:55:06Z","timestamp":1769781306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification and validation of an m1A-score model to predict outcomes and immunomodulation in lung squamous cell carcinoma by integrated analysis of single-cell and bulk RNA sequencing"],"prefix":"10.1007","volume":"17","author":[{"given":"Han","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haihang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yibin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"3","key":"4513_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4513_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4149\/neo_2023_230305N115","volume":"70","author":"ZX Li","year":"2023","unstructured":"Li ZX, Wang F, Sun ZY, Xu C, Zou ZX, Zhao ZX, et al. Prognostic implications of the EGFR polymorphism rs763317 and clinical variables among young Chinese lung cancer population. Neoplasma. 2023;70(3):443\u201350.","journal-title":"Neoplasma"},{"issue":"1","key":"4513_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5334\/aogh.2419","volume":"85","author":"JA Barta","year":"2019","unstructured":"Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85(1):8.","journal-title":"Ann Glob Health"},{"issue":"11","key":"4513_CR4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ccell.2022.09.018","volume":"40","author":"SCM Lau","year":"2022","unstructured":"Lau SCM, Pan Y, Velcheti V, Wong KK. Squamous cell lung cancer: current landscape and future therapeutic options. Cancer Cell. 2022;40(11):1279\u201393.","journal-title":"Cancer Cell"},{"issue":"1","key":"4513_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/mdr2.70004","volume":"1","author":"H Zhang","year":"2025","unstructured":"Zhang H, Zhang G, Xu P, Yu F, Li L, Huang R, et al. Optimized dynamic network biomarker deciphers a high-resolution heterogeneity within thyroid cancer molecular subtypes. Med Research. 2025;1(1):10\u201331.","journal-title":"Med Research"},{"issue":"7846","key":"4513_CR6","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41586-020-03170-y","volume":"590","author":"G Yuan","year":"2021","unstructured":"Yuan G, Flores NM, Hausmann S, Lofgren SM, Kharchenko V, Angulo-Ibanez M, et al. Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature. 2021;590(7846):504\u20138.","journal-title":"Nature"},{"issue":"5","key":"4513_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/blood.2020008743","volume":"138","author":"J Heward","year":"2021","unstructured":"Heward J, Konali L, D\u2019Avola A, Close K, Yeomans A, Philpott M, et al. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood. 2021;138(5):370\u201381.","journal-title":"Blood"},{"key":"4513_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202509344","volume":"12","author":"YQ Ning","year":"2025","unstructured":"Ning YQ, Wang J, Zhang Y, Li H, Jiang Z, Su X, et al. Enhancer reprogramming reveals the tumorigenic role of PTPRZ1 in lung squamous cell carcinoma. Adv Sci (Weinh). 2025;12:e09344.","journal-title":"Adv Sci (Weinh)."},{"issue":"6","key":"4513_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41568-020-0253-2","volume":"20","author":"I Barbieri","year":"2020","unstructured":"Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20(6):303\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"4513_CR10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1042\/BCJ20180445","volume":"476","author":"RJ Ontiveros","year":"2019","unstructured":"Ontiveros RJ, Stoute J, Liu KF. The chemical diversity of RNA modifications. Biochem J. 2019;476(8):1227\u201345.","journal-title":"Biochem J"},{"issue":"7679","key":"4513_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature24456","volume":"551","author":"M Safra","year":"2017","unstructured":"Safra M, Sas-Chen A, Nir R, Winkler R, Nachshon A, Bar-Yaacov D, et al. The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution. Nature. 2017;551(7679):251\u20135.","journal-title":"Nature"},{"issue":"5","key":"4513_CR12","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1093\/nar\/gkad1193","volume":"52","author":"X Gu","year":"2024","unstructured":"Gu X, Zhuang A, Yu J, Yang L, Ge S, Ruan J, et al. Histone lactylation-boosted ALKBH3 potentiates tumor progression and diminished promyelocytic leukemia protein nuclear condensates by m1A demethylation of SP100A. Nucleic Acids Res. 2024;52(5):2273\u201389.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"4513_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01696-5","volume":"15","author":"MZ Xiao","year":"2024","unstructured":"Xiao MZ, Fu JY, Bo LT, Li YD, Lin ZW, Chen ZS. ALKBH1: emerging biomarker and therapeutic target for cancer treatment. Discov Oncol. 2024;15(1):816.","journal-title":"Discov Oncol"},{"key":"4513_CR14","doi-asserted-by":"publisher","first-page":"6578","DOI":"10.1016\/j.csbj.2022.11.045","volume":"20","author":"J Li","year":"2022","unstructured":"Li J, Zhang H, Wang H. N(1)-methyladenosine modification in cancer biology: current status and future perspectives. Comput Struct Biotechnol J. 2022;20:6578\u201385.","journal-title":"Comput Struct Biotechnol J"},{"issue":"8","key":"4513_CR15","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/s43018-025-00977-4","volume":"6","author":"EW Tao","year":"2025","unstructured":"Tao EW, Wang Y, Tan J, Chen Y, Sun TY, Hao Y, et al. TRMT6-mediated tRNA m(1)A modification acts as a translational checkpoint of histone synthesis and facilitates colorectal cancer progression. Nat Cancer. 2025;6(8):1458\u201376.","journal-title":"Nat Cancer"},{"issue":"1","key":"4513_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17735-6","volume":"12","author":"Q Yang","year":"2022","unstructured":"Yang Q, Gong H, Liu J, Ye M, Zou W, Li H. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma. Sci Rep. 2022;12(1):13646.","journal-title":"Sci Rep"},{"issue":"1","key":"4513_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01130-8","volume":"7","author":"C Wang","year":"2022","unstructured":"Wang C, Yu Q, Song T, Wang Z, Song L, Yang Y, et al. The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing. Signal Transduct Target Ther. 2022;7(1):289.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4513_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48700-8","volume":"15","author":"M De Zuani","year":"2024","unstructured":"De Zuani M, Xue H, Park JS, Dentro SC, Seferbekova Z, Tessier J, et al. Single-cell and spatial transcriptomics analysis of non-small cell lung cancer. Nat Commun. 2024;15(1):4388.","journal-title":"Nat Commun"},{"issue":"D1","key":"4513_CR19","doi-asserted-by":"publisher","first-page":"D1425","DOI":"10.1093\/nar\/gkac959","volume":"51","author":"Y Han","year":"2023","unstructured":"Han Y, Wang Y, Dong X, Sun D, Liu Z, Yue J, et al. TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. Nucleic Acids Res. 2023;51(D1):D1425\u201331.","journal-title":"Nucleic Acids Res"},{"key":"4513_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.918140","volume":"13","author":"D Li","year":"2022","unstructured":"Li D, Li K, Zhang W, Yang KW, Mu DA, Jiang GJ, et al. The m6A\/m5C\/m1A regulated gene signature predicts the prognosis and correlates with the immune status of hepatocellular carcinoma. Front Immunol. 2022;13:918140.","journal-title":"Front Immunol"},{"issue":"2","key":"4513_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41576-020-00295-8","volume":"22","author":"D Wiener","year":"2021","unstructured":"Wiener D, Schwartz S. The epitranscriptome beyond m(6)A. Nat Rev Genet. 2021;22(2):119\u201331.","journal-title":"Nat Rev Genet"},{"key":"4513_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7.","journal-title":"BMC Bioinform"},{"key":"4513_CR23","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1016\/j.csbj.2021.08.019","volume":"19","author":"H Zhang","year":"2021","unstructured":"Zhang H, Luo YB, Wu W, Zhang L, Wang Z, Dai Z, et al. The molecular feature of macrophages in tumor immune microenvironment of glioma patients. Comput Struct Biotechnol J. 2021;19:4603\u201318.","journal-title":"Comput Struct Biotechnol J"},{"issue":"7","key":"4513_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"key":"4513_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"issue":"5","key":"4513_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137.","journal-title":"Nat Methods"},{"issue":"1","key":"4513_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218.","journal-title":"Genome Biol"},{"key":"4513_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-1-0716-0327-7_17","volume":"2120","author":"J Racle","year":"2020","unstructured":"Racle J, Gfeller D. EPIC: a tool to estimate the proportions of different cell types from bulk gene expression data. Methods Mol Biol (Clifton, NJ). 2020;2120:233\u201348.","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"issue":"10","key":"4513_CR29","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138.","journal-title":"Nat Med"},{"key":"4513_CR30","doi-asserted-by":"publisher","first-page":"1513040","DOI":"10.3389\/fimmu.2025.1513040","volume":"16","author":"H Gong","year":"2025","unstructured":"Gong H, Zhang Y, Wu X, Pan Y, Wang M, He X, et al. Development and validation of a disulfidptosis-related genes signature for predicting outcomes and immunotherapy in acute myeloid leukemia. Front Immunol. 2025;16:1513040.","journal-title":"Front Immunol"},{"key":"4513_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.108198","volume":"171","author":"H Gong","year":"2024","unstructured":"Gong H, Liu Z, Yuan C, Luo Y, Chen Y, Zhang J, et al. Identification of cuproptosis-related lncRNAs with the significance in prognosis and immunotherapy of oral squamous cell carcinoma. Comput Biol Med. 2024;171:108198.","journal-title":"Comput Biol Med"},{"issue":"5","key":"4513_CR32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33(5):495\u2013502.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"4513_CR33","doi-asserted-by":"publisher","first-page":"bbab260","DOI":"10.1093\/bib\/bbab260","volume":"22","author":"D Maeser","year":"2021","unstructured":"Maeser D, Gruener RF, Huang RS. SoncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6):bbab260.","journal-title":"Brief Bioinform"},{"issue":"1","key":"4513_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01786-y","volume":"22","author":"J Chen","year":"2023","unstructured":"Chen J, Hong JH, Huang Y, Liu S, Yin J, Deng P, et al. EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer. Mol Cancer. 2023;22(1):85.","journal-title":"Mol Cancer"},{"key":"4513_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2022.1610282","volume":"28","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Zhang Z, Wang X, Feng Z, Hong B, Yu D, et al. A novel prognostic factor TIPE2 in bladder cancer. Pathol Oncol Res. 2022;28:1610282.","journal-title":"Pathol Oncol Res"},{"issue":"8","key":"4513_CR36","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"4513_CR37","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","volume":"78","author":"JE Bader","year":"2020","unstructured":"Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol Cell. 2020;78(6):1019\u201333.","journal-title":"Mol Cell"},{"issue":"1","key":"4513_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02460-9","volume":"41","author":"W Li","year":"2022","unstructured":"Li W, Ye K, Li X, Liu X, Peng M, Chen F, et al. YTHDC1 is downregulated by the YY1\/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway. J Exp Clin Cancer Res. 2022;41(1):250.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4513_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02304-0","volume":"21","author":"X Zhu","year":"2021","unstructured":"Zhu X, Yang H, Zhang M, Wu X, Jiang L, Liu X, et al. YTHDC1-mediated VPS25 regulates cell cycle by targeting JAK-STAT signaling in human glioma cells. Cancer Cell Int. 2021;21(1):645.","journal-title":"Cancer Cell Int"},{"issue":"11","key":"4513_CR40","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1038\/s41418-021-00804-0","volume":"28","author":"Y Hou","year":"2021","unstructured":"Hou Y, Zhang Q, Pang W, Hou L, Liang Y, Han X, et al. YTHDC1-mediated augmentation of miR-30d in repressing pancreatic tumorigenesis via attenuation of RUNX1-induced transcriptional activation of Warburg effect. Cell Death Differ. 2021;28(11):3105\u201324.","journal-title":"Cell Death Differ"},{"issue":"20","key":"4513_CR41","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/0008-5472.CAN-22-1695","volume":"82","author":"CL Hong","year":"2022","unstructured":"Hong CL, Yu IS, Pai CH, Chen JS, Hsieh MS, Wu HL, et al. CD248 regulates Wnt signaling in pericytes to promote angiogenesis and tumor growth in lung cancer. Cancer Res. 2022;82(20):3734\u201350.","journal-title":"Cancer Res"},{"key":"4513_CR42","volume":"2022","author":"S Chen","year":"2022","unstructured":"Chen S, Li Y, Zhu Y, Fei J, Song L, Sun G, et al. SERPINE1 overexpression promotes malignant progression and poor prognosis of gastric cancer. J Oncol. 2022;2022:2647825.","journal-title":"J Oncol"},{"issue":"10","key":"4513_CR43","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/emboj.2011.102","volume":"30","author":"E Penna","year":"2011","unstructured":"Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, et al. MicroRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J. 2011;30(10):1990\u20132007.","journal-title":"EMBO J"},{"issue":"4","key":"4513_CR44","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.21037\/tlcr-19-633","volume":"9","author":"Q Li","year":"2020","unstructured":"Li Q, Ma W, Chen S, Tian EC, Wei S, Fan RR, et al. High integrin \u03b13 expression is associated with poor prognosis in patients with non-small cell lung cancer. Transl Lung Cancer Res. 2020;9(4):1361\u201378.","journal-title":"Transl Lung Cancer Res"},{"issue":"10","key":"4513_CR45","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1172\/JCI25673","volume":"116","author":"L Vogt","year":"2006","unstructured":"Vogt L, Schmitz N, Kurrer MO, Bauer M, Hinton HI, Behnke S, et al. VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest. 2006;116(10):2817\u201326.","journal-title":"J Clin Invest"},{"issue":"1","key":"4513_CR46","doi-asserted-by":"publisher","first-page":"eaau7426","DOI":"10.1126\/sciadv.aau7426","volume":"5","author":"X Huang","year":"2019","unstructured":"Huang X, Feng Z, Jiang Y, Li J, Xiang Q, Guo S, et al. VSIG4 mediates transcriptional inhibition of Nlrp3 and Il-1\u03b2 in macrophages. Sci Adv. 2019;5(1):eaau7426.","journal-title":"Sci Adv"},{"issue":"1","key":"4513_CR47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrm.2016.132","volume":"18","author":"BS Zhao","year":"2017","unstructured":"Zhao BS, Roundtree IA, He C. Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol. 2017;18(1):31\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"4513_CR48","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.3390\/ijms24076520","volume":"24","author":"L Tian","year":"2023","unstructured":"Tian L, Wang Y, Tian J, Song W, Li L, Che G. Prognostic value and genome signature of m6A\/m5C regulated genes in early-stage lung adenocarcinoma. Int J Mol Sci. 2023;24(7):6520.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4513_CR49","first-page":"5379","volume":"14","author":"X Wang","year":"2022","unstructured":"Wang X, Yu Q, Yu H, Wang Y, Sun L, Yu L, et al. The prognostic value and multiomic features of m6A-related risk signature in lung adenocarcinoma. Am J Transl Res. 2022;14(8):5379\u201393.","journal-title":"Am J Transl Res"},{"issue":"7","key":"4513_CR50","doi-asserted-by":"publisher","first-page":"10034","DOI":"10.18632\/aging.202761","volume":"13","author":"X Wu","year":"2021","unstructured":"Wu X, Sheng H, Wang L, Xia P, Wang Y, Yu L, et al. A five-m6A regulatory gene signature is a prognostic biomarker in lung adenocarcinoma patients. Aging (Albany NY). 2021;13(7):10034\u201357.","journal-title":"Aging (Albany NY)"},{"key":"4513_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.763027","volume":"11","author":"C Weng","year":"2021","unstructured":"Weng C, Wang L, Liu G, Guan M, Lu L. Identification of a N6-Methyladenosine (m6A)-related lncRNA signature for predicting the prognosis and immune landscape of lung squamous cell carcinoma. Front Oncol. 2021;11:763027.","journal-title":"Front Oncol"},{"issue":"7","key":"4513_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012069","volume":"13","author":"P Zhang","year":"2025","unstructured":"Zhang P, Zhang M, Liu J, Zhou Z, Zhang L, Luo P, et al. Mitochondrial pathway signature (MitoPS) predicts immunotherapy response and reveals NDUFB10 as a key immune regulator in lung adenocarcinoma. J Immunother Cancer. 2025;13(7):e012069.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"4513_CR53","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18(12):792\u2013804.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"4513_CR54","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/cam4.993","volume":"6","author":"A Zhang","year":"2017","unstructured":"Zhang A, Qian Y, Ye Z, Chen H, Xie H, Zhou L, et al. Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma. Cancer Med. 2017;6(2):463\u201370.","journal-title":"Cancer Med"},{"issue":"1","key":"4513_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39553-z","volume":"9","author":"B Gok Yavuz","year":"2019","unstructured":"Gok Yavuz B, Gunaydin G, Gedik ME, Kosemehmetoglu K, Karakoc D, Ozgur F, et al. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1(+) TAMs. Sci Rep. 2019;9(1):3172.","journal-title":"Sci Rep"},{"issue":"7","key":"4513_CR56","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s00262-023-03428-0","volume":"72","author":"S Wang","year":"2023","unstructured":"Wang S, Fan G, Li L, He Y, Lou N, Xie T, et al. Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC. Cancer Immunol Immunother. 2023;72(7):2423\u201342.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"4513_CR57","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.18632\/aging.204685","volume":"15","author":"Y Wang","year":"2023","unstructured":"Wang Y, Lv W, Yi Y, Zhang Q, Zhang J, Wu Y. A novel signature based on cancer-associated fibroblast genes to predict prognosis, immune feature, and therapeutic response in breast cancer. Aging. 2023;15(9):3480\u201397.","journal-title":"Aging"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04513-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04513-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04513-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:03:14Z","timestamp":1772024594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04513-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4513"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04513-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study using clinical samples was approved by the Medical Ethics Committee of Xiangya Hospital (No. 2023111626) and conducted in accordance with the Declaration of Helsinki and applicable national regulations. Research involving human research participants have been performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients prior to surgery.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to publish has been obtained from all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"366"}}